- $5.10bn
- $6.31bn
- $3.93bn
- 93
- 62
- 90
- 96
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,337 | 2,614 | 3,409 | 4,321 | 3,931 |
Cost of Revenue | |||||
Gross Profit | 694 | 506 | 806 | 885 | 839 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 3,042 | 2,593 | 2,955 | 3,932 | 3,405 |
Operating Profit | 295 | 21 | 454 | 389 | 526 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 255 | -33 | 406 | 335 | 451 |
Provision for Income Taxes | |||||
Net Income After Taxes | 185 | -231 | 281 | 233 | 479 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 157 | -238 | 250 | 209 | 445 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 155 | -238 | 247 | 206 | 437 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.66 | -1.87 | 4.86 | 6.13 | 8.05 |
Dividends per Share |